[ad_1]
Genomic Health, Inc. (NASDAQ: GHDX) obtained an average "Hold" recommendation from the twelve research firms that cover the company, MarketBeat Ratings reports: Two financial badysts evaluated the title with a sales note, six badigned a reserve note, one badigned a purchase note and three issued a high purchase note on the company. Analysts who published a report on the stock over the past year is $ 34,22
Several badysts have recently commented on GHDX.SaskaskClub shares raised Genomic Health's rating of " hold "on a note" buy "in a research note Friday, March 30, ValuEngine took Genomic Health from a" sell "note to a" hold "note in a research note on Thursday, April 12 2009. Deutsche Bank raised its price target on Genomic Health from $ 32.00 to $ 34.00 note in a research note on Thursday, May 3rd. Zacks Investment Research took Genomic Health from a "hold" rating to a "strong buy" rating and set a price target of $ 42.00 on the stock in a research note on Wednesday, May 9th. Finally, Canaccord Genuity raised its price target on Genomic Health from $ 41.00 to $ 45.00 and awarded the company a purchase note in a research note on Monday, June 4th.
In addition, Steven Shak sold 5,500 shares of Genomic Health stock in a transaction dated Monday, June 11. The stock was sold at an average price of $ 50.22, for a total transaction of $ 276,210.00. The transaction has been disclosed in a legal deposit with the Securities & Exchange Commission, which is accessible via this hyperlink. Kimberly J. Popovits also sold 10,000 shares of Genomic Health in an operation dated Monday, July 16th. The stock was sold at an average price of $ 53.27, for a total value of $ 532,700.00. The disclosure for this sale can be found here. Insiders sold 141,411 shares valued at $ 6,477,955 during the last quarter. 45.80% of the shares are currently held by insiders.
Several major investors have recently changed their holdings of GHDX. Point72 Asset Management LP increased its Genomic Health equity holdings by 136.0% in the first quarter. Point72 Asset Management LP now holds 388,400 medical research company shares worth $ 12,153,000 after the acquisition of 223,800 additional shares during the period. Renaissance Technologies LLC increased its position in Genomic Health shares by 16.2% in the fourth quarter. Renaissance Technologies LLC now holds 1,012,000 shares of the medical research company valued at $ 34,610,000 after purchasing an additional 141,300 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in Genomic Health in the fourth quarter, valued at approximately $ 2,588,000. Carillon Tower Advisers Inc. has acquired a new stake in Genomic Health in the first quarter worth approximately $ 2,358,000. Finally, Russell Investments Group Ltd. increased its position in Genomic Health shares by 894.1% in the first quarter. Russell Investments Group Ltd. now holds 42,449 shares of the medical research business valued at $ 1,328,000 after purchasing 38,179 additional shares during the last quarter. Institutional investors hold 89.77% of the shares of the company.
Genomic Health shares fell $ 1.12 to $ 57.19 on Tuesday, according to MarketBeat Ratings reports. The company had a trading volume of 1,128 shares, compared to its average volume of 301,969. Genomic Health has a 12-month low of $ 26.54 and a high of $ 12.83 in 12 months. The company has a market capitalization of $ 1.97 billion, a price / earnings ratio of $ 5,737.00 and a beta of $ 0.55.
Genomic Health (NASDAQ: GHDX) last published its quarterly results on Wednesday, May 2nd. The medical research company reported earnings per share (EPS) of $ 0.13 for the quarter, up $ 0.08 from Thomson Reuters' consensus estimate of $ 0.05. Genomic Health recorded a return on equity of 3.15% and a negative net margin of 1.95%. The company achieved a turnover of $ 92.60 million for the quarter, against badysts' forecasts of $ 88.95 million. During the same period last year, the company earned $ 0.02 of EPS. The business turnover of the company increased by 12.5% from one year to the next. The sell-side badysts predict that Genomic Health will post 0.47 earnings per share for the current year.
Genomics Business Profile
Genomic Health, Inc., a healthcare company, provides exploitable genomic information to personalize cancer treatment decisions around the world . It develops and markets genomic clinical laboratory services that badyze the underlying biology of cancer, enabling physicians and patients to make individualized treatment decisions.
History: Understanding the Price / Profit Ratio
Receive News & Reviews for Genomic Health Daily – Enter your e-mail address Mail below to receive a concise summary of the latest news and badyst ratings for Genomic Health and related companies with MarketBeat.com's free daily e-newsletter.
Source link
